The global NUT midline carcinoma treatment market was valued at approximately USD 21.44 billion in 2024 and is projected to grow at a CAGR of around 14% from 2025 to 2034, driven by increasing incidence of rare aggressive carcinomas, advancements in targeted therapeutics, and rising awareness among oncologists and patients worldwide. North America accounts for the largest market share,...